Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Huabo Biopharm (Shanghai) Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, requiring coordination across separate examination tracks.
DONOGHUE, BRITTNEY ERIN is the busiest listed examiner, with 1 pending matter. Counsel should preserve consistency across the portfolio while tailoring each response to the examiner and art unit handling that matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039733 | ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038627 | BISPECIFIC ANTIBODY AND USE THEREOF | PETERS, ALEC JON | 22d |
| 18039733 | ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18039733 | ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18038627 | BISPECIFIC ANTIBODY AND USE THEREOF | PETERS, ALEC JON | 1641 | §112 | Final Rejection | 22d | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuabo Biopharm (Shanghai) Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brittney Erin Donoghue has the most, with 1 of Huabo Biopharm (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
